Search

Contemporary therapy of Alzheimer's disease is only symptomatic, not causal (brain cholinesterases inhibitors, memantine). That is why the plenty of pharmacotherapeutical approaches are in clinical investigation. Main sphere of investigation represents the investigation of the strategies affecting two pathological proteins, associated with Alzheimer's disease - beta-amyloid and Tau-protein. Wide spectrum of drugs with different way of action is tested, but it is difficult to say, which of this drugs is promising. [ABSTRACT FROM AUTHOR]

An article gives an overview of the currently most-watched genetic factors of Alzheimer's disease. The main hypothesis is: certain genetic polymorphisms influence the development and course of the clinical picture of Alzheimer's disease. Purpose of the study is figuring out how polymorphisms modify the clinical picture of dementia, how certain clinical features correlate with certain genetic abnormalities. Knowing the connection between genetic polymorphisms and clinical features (such as the predominant behavior disorders, activities of daily living, mood disorders) and genetic examination of polymorhisms in turn would lead to improve diagnosis and therapy of the disease. Also discovery of a new polymorphism influencing the emergence of a clinical picture AD, would mean the inventing a new biomarker AD, which would serve to early diagnosis and early initiation of therapy at a stage before the onset of dementia. In the genetics, there are important Genome-wide association studies (GWAS), which are useful first of all for identifying of genetic susceptibility for multifactorial diseases - genes (or genotypes constitued from other allelas of this genes), which increased or decreased of risk of disease. Such gebnotypes we find solurelatively simply - they occur significantly often or significantly scarcely ever. In the group of patients in comparison with the control group of healthy people. [ABSTRACT FROM AUTHOR]